Eli Lilly and Company (NYSE:LLY) has earned an average recommendation of “Hold” from the twenty research firms that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $90.09.
Several research firms have weighed in on LLY. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a report on Wednesday. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Jefferies Group reissued a “buy” rating and issued a $89.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd.
Eli Lilly and (LLY) traded down $1.39 during midday trading on Thursday, reaching $86.50. The company’s stock had a trading volume of 4,388,368 shares, compared to its average volume of 3,686,396. Eli Lilly and has a 1-year low of $69.66 and a 1-year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The stock has a market cap of $95,475.95, a PE ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter last year, the business posted $0.88 EPS. The business’s revenue was up 9.0% on a year-over-year basis. equities analysts forecast that Eli Lilly and will post 4.21 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently 98.58%.
In related news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 841,088 shares of company stock valued at $72,120,286 in the last three months. Corporate insiders own 0.20% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Accredited Investors Inc. increased its holdings in shares of Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after purchasing an additional 14 shares in the last quarter. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after purchasing an additional 19 shares in the last quarter. Oakworth Capital Inc. increased its holdings in shares of Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after purchasing an additional 20 shares in the last quarter. Sfmg LLC increased its holdings in shares of Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after purchasing an additional 20 shares in the last quarter. Finally, Jackson Grant Investment Advisers Inc. increased its holdings in shares of Eli Lilly and by 0.7% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after purchasing an additional 24 shares in the last quarter. 76.42% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Company (LLY) Receives Average Recommendation of “Hold” from Brokerages” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/12/14/eli-lilly-and-company-lly-receives-average-recommendation-of-hold-from-brokerages.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.